Breast Cancer

, Volume 24, Issue 6, pp 742–747 | Cite as

Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size

  • Zahra Malek-Hosseini
  • Sina Jelodar
  • Abdolrasoul Talei
  • Abbas Ghaderi
  • Mehrnoosh Doroudchi
Original Article



Breast cancer is the leading type of cancer in Iranian women and affects them at least one decade younger than their counterparts in developed countries. Breast tumor progression and metastasis is accompanied by a decrease in the membranous expression of Syndecan-1 and an increase in its shedding. We measured the level of soluble Syndecan-1 in the sera of Iranian patients with breast cancer.


The study population included 61 chemotherapy-naïve breast cancer patients and 30 age/sex-matched healthy individuals. Blood was collected by venipuncture method and serum was separated, aliquoted and kept at −40 °C until used. A commercial ELISA was used to detect Syndecan-1 levels in the sera.


Soluble Syndecan-1 levels were increased in the sera of patients with breast cancer compared to healthy controls (87.89 ± 89.29 vs. 47.57 ± 46.46 ng/ml, p = 0.005). There was a positive correlation between soluble Syndecan-1 levels and tumor size (p = 0.017). The serum level of Syndecan-1 in patients without calcification showed a trend of increase compared to that of patients with calcification (108.80 ± 101.76 vs. 59.82 ± 57.13 ng/ml).


The positive correlation between soluble Syndecan-1 levels and tumor size in the present study highlights the importance of different varieties (cell-bound and soluble) of this molecule in the breast tumor progression and their significance as tumor biomarkers.


Breast cancer Syndecan-1 Serum Tumor size 



This work was performed as part of Sina Jelodar dissertation as a requirement for graduation as a general practitioner from Shiraz Medical School (Shiraz, Iran). This project was financially supported by a Grant (90-01-2779) from Shiraz University of Medical Sciences and was performed and supported by Shiraz Institute for Cancer Research, Shiraz, Iran (Grant ICR-100-502).

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

12282_2017_773_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 18 kb)


  1. 1.
    Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma–rare types: review of the literature. Ann Oncol. 2009;20(11):1763–70.CrossRefPubMedGoogle Scholar
  2. 2.
    WHO. Breast cancer: prevention and control. In: Organization WH, editor.Google Scholar
  3. 3.
    Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730–56.CrossRefPubMedGoogle Scholar
  4. 4.
    Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: ten-year national cancer registry data report. Cancer Epidemiol. 2015;39(4):519–27.CrossRefPubMedGoogle Scholar
  5. 5.
    Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev. 2004;5(1):24–7.PubMedGoogle Scholar
  6. 6.
    Movahedi M, Haghighat S, Khayamzadeh M, Moradi A, Ghanbari-Motlagh A, Mirzaei H, et al. Survival rate of breast cancer based on geographical variation in Iran, a national study. Iran Red Crescent Med J. 2012;14(12):798–804.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Rahimzadeh M, Pourhoseingholi MA, Kavehie B. Survival rates for breast cancer in iranian patients: a meta-analysis. Asian Pac J Cancer Prev. 2016;17(4):2223–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist. 2006;11(6):541–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Purushothaman A, Sanderson RD. Atlas of genetics and cytogenetics in oncology and haematology. 2008 [cited 2016 September].
  10. 10.
    Bartlett AH, Hayashida K, Park PW. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cells. 2007;24(2):153–66.PubMedGoogle Scholar
  11. 11.
    Gotte M, Echtermeyer F. Syndecan-1 as a regulator of chemokine function. Sci World J. 2003;3:1327–31.CrossRefGoogle Scholar
  12. 12.
    Kharabi Masouleh B, Ten Dam GB, Wild MK, Seelige R, van der Vlag J, Rops AL, et al. Role of the heparan sulfate proteoglycan Syndecan-1 (CD138) in delayed-type hypersensitivity. J Immunol (Baltimore, Md: 1950). 2009;182(8):4985–93.Google Scholar
  13. 13.
    Hayashida K, Parks WC, Park PW. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood. 2009;114(14):3033–43.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Fears CY, Woods A. The role of syndecans in disease and wound healing. Matrix Biol. 2006;25(7):443–56.CrossRefPubMedGoogle Scholar
  15. 15.
    Akl MR, Nagpal P, Ayoub NM, Prabhu SA, Gliksman M, Tai B, et al. Molecular and clinical profiles of Syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget. 2015;6(30):28693–715.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Shegefti MS, Malekzadeh M, Malek-Hosseini Z, Khademi B, Ghaderi A, Doroudchi M. Reduced serum levels of syndecan-1 in patients with tongue squamous cell carcinoma. Laryngoscope. 2016;126(5):E191–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Rintala M, Inki P, Klemi P, Jalkanen M, Grenman S. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. Gynecol Oncol. 1999;75(3):372–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Can Res. 2001;61(14):5562–9.Google Scholar
  19. 19.
    Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 2000;88(1):12–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, et al. Differential roles for membrane-bound and soluble Syndecan-1 (CD138) in breast cancer progression. Carcinogenesis. 2009;30(3):397–407.CrossRefPubMedGoogle Scholar
  21. 21.
    Szatmari T, Otvos R, Hjerpe A, Dolora K. Syndecan-1 in cancer: implications for cell signaling, differentiation, and prognostication. Dis Mark. 2015;2015:796052. doi: 10.1155/2015/796052.Google Scholar
  22. 22.
    Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol. 2012;31(1):3–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Kim SY, Choi EJ, Yun JA, Jung ES, Oh ST, Kim JG, et al. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases. Int J Med Sci. 2015;12(2):92–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kato M, Saunders S, Nguyen H, Bernfield M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell. 1995;6(5):559–76.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, et al. Shift of Syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer. 2004;40(9):1373–82.CrossRefPubMedGoogle Scholar
  26. 26.
    Subramanian SV, Fitzgerald ML, Bernfield M. Regulated shedding of Syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem. 1997;272(23):14713–20.CrossRefPubMedGoogle Scholar
  27. 27.
    Ishikawa T, Kramer RH. Sdc1 negatively modulates carcinoma cell motility and invasion. Exp Cell Res. 2010;316(6):951–65.CrossRefPubMedGoogle Scholar
  28. 28.
    Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, et al. Cleavage of Syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem. 2003;278(42):40764–70.CrossRefPubMedGoogle Scholar
  29. 29.
    Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, et al. High Syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003;98(3):474–83.CrossRefPubMedGoogle Scholar
  30. 30.
    Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C. Prognostic value of Syndecan-1 expression in breast cancer. Oncology. 2004;67(1):11–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, et al. Prognostic impact of Syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer. 2008;98(12):1993–8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Sanaee MN, Malekzadeh M, Khezri A, Ghaderi A, Doroudchi M. Soluble CD138/Syndecan-1 increases in the sera of patients with moderately differentiated bladder cancer. Urol Int. 2015;94(4):472–8.CrossRefPubMedGoogle Scholar
  33. 33.
    The Human Protein Atlas [cited 2016 September].
  34. 34.
    Yang N, Morrison CD, Liu P, Miecznikowski J, Bshara W, Han S, et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle (Georgetown, Tex). 2012;11(15):2922–30.Google Scholar
  35. 35.
    Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566–84.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Stiehl DP, Bordoli MR, Abreu-Rodriguez I, Wollenick K, Schraml P, Gradin K, et al. Non-canonical HIF-2alpha function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop. Oncogene. 2012;31(18):2283–97.CrossRefPubMedGoogle Scholar
  37. 37.
    Ansell A, Jedlinski A, Johansson AC, Roberg K. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells. J Oral Pathol Med. 2016;45(1):9–16.CrossRefPubMedGoogle Scholar
  38. 38.
    Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ 2nd. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther. 2009;122(1):1–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Ling H, Liu ZB, Xu LH, Xu XL, Liu GY, Shao ZM. Malignant calcification is an important unfavorable prognostic factor in primary invasive breast cancer. Asia Pac J Clin Oncol. 2013;9(2):139–45.CrossRefPubMedGoogle Scholar
  40. 40.
    Nyante SJ, Lee SS, Benefield TS, Hoots TN, Henderson LM. The association between mammographic calcifications and breast cancer prognostic factors in a population-based registry cohort. Cancer. 2016;. doi: 10.1002/cncr.30281.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2017

Authors and Affiliations

  1. 1.Department of ImmunologySchool of Medicine, Shiraz University of Medical SciencesShirazIran
  2. 2.Breast Disease Research CenterShiraz University of Medical SciencesShirazIran
  3. 3.Institute for Cancer ResearchShiraz University of Medical SciencesShirazIran

Personalised recommendations